Synta Presents Positive One-Year Follow-up Results for GALAXY-1 Trial of Ganetespib in NSCLC at 15th World Conference on Lung Cancer
October 26, 2013 at 10:12 AM EDT
Synta Pharmaceuticals Corp. (NASDAQ: SNTA ) today announced presentation of results from the GALAXY-1 trial, a global, randomized, multi-center study designed to identify the patients with advanced non-small cell
